North America Apheresis Market

North America Apheresis Market Size (2023 to 2028)

The Apheresis Market size in North America was worth USD 0.83 billion in 2023. It is estimated to be growing at a CAGR of 10.87% to reach USD 1.39 billion by 2028 during the forecast period.

The U.S. Government has supported R & D funding of Apheresis through its benefit programs such as Medicaid, Medicare, veterans’ health administration, military, and employee insurance programs. Medicare provides coverage for apheresis regardless of whether the procedure is performed in a hospital or a blood center. Besides, private insurers have recently begun to examine apheresis procedures and issue policy statements about coverage closely.

The rising aging population in North American countries like the United States and Canada is estimated to favor market growth during the forecast period. As per the statistics published by the U.S. Census Bureau, the number of Americans aged 65 years and above is expected to escalate from 46 million to 98 million by 2060. Y-O-Y growth in the incidence of hematologic diseases is predicted to accelerate the development of the North American apheresis market. Growing blood disorders incidence, using advanced technology machines for differentiating blood components is expected to support market growth.

In North America, the lack of donor availability and histocompatibility are expected to restrain the market growth. Risks and obstacles associated with the apheresis market may hamper the market growth during the period. Side effects with replacement fluids impede the growth. Lack of awareness and high cost hinders market growth.

This research report on the North America Apheresis Market has been segmented and sub-segmented into the following categories:

• By Product: Devices and Disposables
• By Procedure: Donor, Therapeutic, and Photopheresis
• By Application: Renal Diseases, Neurology, Cancer, Hematology, Autoimmune Diseases, and Cardiovascular Diseases
• By Technology: Centrifuge and Membrane Separation
• By End User: Private Blood Collection Centres, Public Blood Collection Centres, and Hospitals
• By Country: The United States, Canada, and Rest of North America

Regional Analysis:

As of 2019, North America leads the Global Apheresis market, accounting for more than 34% of the total market share. North America has the largest market in 2019 due to its healthcare infrastructure and high demand for plasma to produce plasma-derived medicines. The disposables products segment is expected to have the largest share in the North America apheresis market.

The United States is projected to lead the market in this region due to the growing number of apheresis methods and their enhancements, increasing the number of apheresis centers, and accepting well-developed infrastructure. Moreover, encouraging reimbursement policies and the possibility of developed blood collection technologies that bolster the market. 

Following the United States, the Canadian market is leading the North American region. An increasing number of substantial market players in the area augment research and development activities related to product manufacturing and marketing activities. Y-O-Y increase in chronic kidney diseases is to contribute more towards market growth. The surging number of transfusion services and around 71.9 per 1,000 individuals and nearly 4 million are diagnosed with chronic kidney diseases.

Companies playing a dominant role in the North American apheresis Market profiled in this report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.